In This Story
Zenas BioPharma Inc. (ZBIO+6.81%) has submitted its Form 10-K filing for the fiscal year ended December 31, 2024.
The filing details the company's financial position, highlighting a net loss of $157 million for the year, with an accumulated deficit of $387.4 million. The company anticipates incurring substantial and increasing losses as it advances the development of its product candidates.
Zenas BioPharma's lead product candidate, obexelimab, is being developed for multiple immunology and inflammation diseases, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company is conducting a global Phase 3 trial for obexelimab in IgG4-RD and expects to report topline data by year-end 2025.
The company has in-licensed the rights to develop and commercialize obexelimab, ZB002, and ZB004 from Xencor, and holds global rights to these assets. Zenas BioPharma is also engaged in strategic collaborations, including a license agreement with Bristol-Myers Squibb for the development and commercialization of obexelimab in certain territories.
Zenas BioPharma faces significant risks, including potential competition from other pharmaceutical companies, the need for substantial additional financing, and the inherent uncertainties of clinical development. The company acknowledges that its future success depends on the successful development, regulatory approval, and commercialization of its product candidates.
The company is dependent on its management team and key personnel, and any loss of such individuals could delay or prevent the successful development of its product pipeline.
Zenas BioPharma's product candidates are subject to extensive government regulation, and the company must comply with numerous regulatory requirements to conduct clinical trials and seek marketing approvals.
The company is focused on expanding its operations and managing growth, which includes increasing its employee base and establishing commercial capabilities.
Zenas BioPharma's ability to generate revenue is contingent upon obtaining regulatory approvals and achieving market acceptance of its product candidates, which may be influenced by pricing, reimbursement, and competition.
The filing also outlines the company's intellectual property strategy, emphasizing the importance of obtaining and maintaining patent protection for its product candidates.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Zenas BioPharma Inc. annual 10-K report dated March 11, 2025. To report an error, please email earnings@qz.com.